Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Inclusion Criteria: * Must have recurrent B-cell NHL and measurable disease * No anti-lymphoma therapy within the past 4 weeks * Must have a good performance status (less than or equal to 2 Zubrod, greater than or equal to 60 Karnofsky) * Absolute neutrophil count (ANC) greater than or equal to 1,000 * Platelets greater than or equal to 75,000 * Hemoglobin greater than or equal to 10 g/dL * Bilirubin less than or equal to 1.5 mg/dL * Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT) less than or equal to 2 times upper limit of laboratory normals * Alkaline phosphatase less than or equal to 2 times upper limit of laboratory normals * Serum creatinine less than or equal to 1.8 mg/dL * Must sign a consent form, and must have a life expectancy of greater than 12 weeks * No more than 3 prior chemotherapy regimens * Patients who are either Rituximab naive, have previously responded to Rituximab, or are refractory to Rituximab used alone or in combination with chemotherapy Exclusion Criteria: * Human immunodeficiency virus (HIV) positive * Active infection or history of opportunistic infections * Pregnant women and women of childbearing age who are not practicing adequate contraception; men who are not willing to use an effective method of contraception * History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for 5 or more years) * Active autoimmune disease * Other significant medical diseases * Patients with chronic lymphocytic leukemia (CLL) * Prior exposure to G3139